Skip to main content
NCBI home page
Indian Journal of Surgical Oncology logoLink to Indian Journal of Surgical Oncology
. 2011 Sep 3;2(2):133–140. doi: 10.1007/s13193-011-0086-2

Mastectomy and Contralateral Prophylactic Mastectomy Rates: An Institutional Review

Sameer Damle 1, Christine B Teal 1,✉, Joanne J Lenert 2, Elizabeth C Marshall 2, Qing Pan 3, Anita P McSwain 1
PMCID: PMC3373170  PMID: 22696239

Abstract

Background. Breast conservation surgery (BCS) followed by radiation is as effective as mastectomy for long-term survival and is considered standard of care for early-stage breast cancer. An increasing number of patients are opting for cancer-side mastectomies (CM) and often contralateral prophylactic mastectomies (CPM). Our study investigates if there are increasing trends in our patient population toward CM and CPM and identifies common factors associated with those electing to have more extensive surgery.

Methods. A retrospective analysis was performed on 812 breast cancer surgeries between January 2001 and December 2009 at The George Washington University Breast Care Center. BCS-eligible patients who elected to have BCS were compared with those who chose CM. Patients who underwent CM were compared with patients undergoing CM and CPM.

Results. A personal or family history of breast cancer and larger tumor size were positively associated with choosing CM in BCS-eligible patients. A nonstatistically significant trend toward CM was seen in younger patients. Age, family history, fewer children, Caucasian race, and reconstructive surgery were positively associated with choosing CPM.

Conclusion. Mastectomy rates at this institution have not shown the recent sharp increase observed by some authors. The association of age, race, family history, and parity with CPM has been corroborated in multiple studies. However, there is disagreement between statistically significant findings among investigators evaluating factors associated with CPM, and there is limited data in the literature characterizing BCS-eligible patients who chose CM. Larger prospective studies are necessary to further evaluate CM and CPM rates.

Footnotes

This article was originally published in Annals of Surgical Oncology, volume 18, pp. 1356–1363, DOI 10.1245/s10434-010-1434-0.

References

  • 1.NIH Consensus Development Conference statement on the treatment of early-stage breast cancer. J Natl Cancer Inst Monogr. 1992;11:1–5. [PubMed]
  • 2.McGuire KP, Santillan AA, Kaur P, Meade T, Parbhoo J, Mathias M, et al. A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682–90. doi: 10.1245/s10434-009-0635-x. [DOI] [PubMed] [Google Scholar]
  • 3.Sprundel TC, Schmidt MK, Rookus MA, Brohet R, Asperen CJ, Rutgers EJ, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA 2 mutation carriers. Br J Cancer. 2005;93:287–92. doi: 10.1038/sj.bjc.6602703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938–43. doi: 10.1200/JCO.2001.19.19.3938. [DOI] [PubMed] [Google Scholar]
  • 5.Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for prevention of breast cancer. Cochrane Database Syst Rev. 2004;4:CD002748. [DOI] [PubMed]
  • 6.Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102:1–9. doi: 10.1093/jnci/djp493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M. Society of Surgical Oncology: position statement on prophylactic mastectomy. Ann Surg Oncol. 2007;14:2425–7. doi: 10.1245/s10434-007-9447-z. [DOI] [PubMed] [Google Scholar]
  • 8.Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–42. doi: 10.1093/jnci/88.21.1529. [DOI] [PubMed] [Google Scholar]
  • 9.National Accreditation for Breast Centers 2009 Standards Manual. Available at: http://accreditedbreastcenters.org/standards/2009standardsmanual.pdf. Accessed 11 March 2010.
  • 10.Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992;326:1097–101. doi: 10.1056/NEJM199204233261701. [DOI] [PubMed] [Google Scholar]
  • 11.McCahill LE, Privette AR, Hart MR, James TA. Are mastectomy rates a reasonable quality measure of breast cancer surgery? Am J Surg. 2009;197:216–21. doi: 10.1016/j.amjsurg.2007.12.056. [DOI] [PubMed] [Google Scholar]
  • 12.Nold RJ, Beamer RL, Helmer SD, McBoyle MF. Factors influencing a woman’s choice to undergo breast-conserving surgery versus modified radical mastectomy. Am J Surg. 2000;180:413–8. doi: 10.1016/S0002-9610(00)00501-8. [DOI] [PubMed] [Google Scholar]
  • 13.Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol. 2009;16:2691–6. doi: 10.1245/s10434-009-0547-9. [DOI] [PubMed] [Google Scholar]
  • 14.Crowe JP, Patrick RJ, Rim A. The importance of preoperative breast MRI for patients newly diagnosed with breast cancer. Breast J. 2009;15:52–60. doi: 10.1111/j.1524-4741.2008.00671.x. [DOI] [PubMed] [Google Scholar]
  • 15.Bedrosian I, Mick R, Orel SG, Schnall M, Reynolds C, Spitz FR, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003;98:468–73. doi: 10.1002/cncr.11490. [DOI] [PubMed] [Google Scholar]
  • 16.Brem RF, Schoonjans JM, Kieper DA, Majewski S, Goodman S, Civelek C. High-resolution scintimammography: a pilot study. J Nucl Med. 2007;43:909–15. [PubMed] [Google Scholar]
  • 17.Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94. doi: 10.1093/jnci/dji021. [DOI] [PubMed] [Google Scholar]
  • 18.Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179–84. doi: 10.1023/A:1008400706949. [DOI] [PubMed] [Google Scholar]
  • 19.Chagpar AB, Studts JL, Scoggins CR, Martin RC, II, Carlson DJ, Laidley AL, et al. Factors associated with surgical options for breast carcinoma. Cancer. 2006;106:1462–6. doi: 10.1002/cncr.21728. [DOI] [PubMed] [Google Scholar]
  • 20.Wang J, Kollias J, Boult M, Babidge W, Zorbas HN, Roder D, et al. Patterns of surgical treatment for women with breast cancer in relation to age. Breast J. 2010;16:60–5. doi: 10.1111/j.1524-4741.2009.00828.x. [DOI] [PubMed] [Google Scholar]
  • 21.Lee MC, Rogers K, Griffith K, Diehl KA, Breslin TM, Cimmino VM, et al. Determinants of breast conservation rates: reasons for mastectomy at a comprehensive cancer center. Breast J. 2009;15:34–40. doi: 10.1111/j.1524-4741.2008.00668.x. [DOI] [PubMed] [Google Scholar]
  • 22.Moreland A, Zhang Y, Dissanaike S, Arya R. Private insurance is the strongest predictor of women receiving breast conservation surgery for breast cancer. Am J Surg. 2009;198:787–91. doi: 10.1016/j.amjsurg.2009.05.031. [DOI] [PubMed] [Google Scholar]
  • 23.Levy, Francesca. America’s 25 Richest Counties. Available at: http://www.forbes.com/2010/03/04/america-richest-counties-lifestylereal-estate-wealthy-suburbs.html. Accessed 11 March 2010.
  • 24.Reuters. Washington area richest, most educated in US. Available at: http://www.washingtonpost.com/wp-dyn/content/article/2006/06/08/AR2006060800133_pf.html. Accessed 11 March 2010.
  • 25.Albain KS, Green SR, Lichter AS, Hutchins LF, Wood WC, Henderson IC, et al. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996;14:3009–17. doi: 10.1200/JCO.1996.14.11.3009. [DOI] [PubMed] [Google Scholar]
  • 26.Verkooijen HM, Rapiti E, Fioretta G, Vinh-Hung V, Keller J, Benhamou S, et al. Impact of a positive family history on diagnosis, management, and survival of breast cancer: different effects across socio-economic groups. Cancer Causes Control. 2009;20:1689–96. doi: 10.1007/s10552-009-9420-1. [DOI] [PubMed] [Google Scholar]
  • 27.Osteen RT. Reconstruction after mastectomy. Cancer. 1995;76:2070–4. doi: 10.1002/1097-0142(19951115)76:10+<2070::AID-CNCR2820761327>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 28.Malata CM, McIntosh SA, Purushotham AD. Immediate breast reconstruction after mastectomy for cancer. Br J Surg. 2000;87:1455–72. doi: 10.1046/j.1365-2168.2000.01593.x. [DOI] [PubMed] [Google Scholar]
  • 29.Alderman AK, Hawley ST, Waljee J, Morrow M, Katz SJ. Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction. Cancer. 2007;109:1715–20. doi: 10.1002/cncr.22598. [DOI] [PubMed] [Google Scholar]
  • 30.Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16:2697–704. doi: 10.1245/s10434-009-0641-z. [DOI] [PubMed] [Google Scholar]
  • 31.Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical management. J Clin Oncol. 2007;25:5203–9. doi: 10.1200/JCO.2007.12.3141. [DOI] [PubMed] [Google Scholar]
  • 32.Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7. doi: 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 33.Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180:439–45. doi: 10.1016/S0002-9610(00)00505-5. [DOI] [PubMed] [Google Scholar]
  • 34.Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group. J Clin Oncol. 2008;26:1093–7. doi: 10.1200/JCO.2007.12.6078. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Surgical Oncology are provided here courtesy of Springer

RESOURCES